Long-Term Impacts of COVID-19 on Severe Exacerbation and Mortality in Adult Asthma: A Nationwide Population-Based Cohort Study

Lee, Hyun; Kim, Bo-Guen; Jeong, Cho Yun; Park, Dong Won; Park, Tai Sun; Moon, Ji-Yong; Kim, Tae-Hyung; Sohn, Jang Won; Yoon, Ho Joo; Kim, Jong Seung; Kim, Sang-Heon

doi:10.1016/j.jaip.2024.03.035

Cited by 2 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24] However, existing studies into the relationship between incident COVID-19 and asthma exacerbations have not been carried out in boosted populations. [22,23,25] Additionally, these studies have not considered whether exacerbation risk from breakthrough SARS-CoV-2 infection is affected by time since vaccination, which is likely to be longer in people with well controlled asthma, who may still experience severe asthma exacerbations [26] but are currently not eligible for booster vaccinations. [7] To address these knowledge gaps, we therefore aimed to assess the association between time since vaccination and various characteristics of breakthrough infections, including symptom severity, symptom duration, and acute changes to health-related quality of life.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…[7] Among those currently eligible for annual booster vaccination are people with poorly controlled asthma. [7] In this population, the protective effect of vaccination is twofold: on the one hand, vaccination protects against severe COVID-19, for which poorly controlled asthma is a risk factor; [21] on the other, by reducing the incidence and severity of breakthrough infections, vaccination may also protect against asthma exacerbations triggered by incident COVID-19 [22,23] and subsequent worsening of asthma control. [24] However, existing studies into the relationship between incident COVID-19 and asthma exacerbations have not been carried out in boosted populations.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study

Vivaldi,

Talaei,

Pfeffer

et al. 2024

Preprint

View full text Add to dashboard Cite

BackgroundIn several countries, COVID-19 booster vaccinations are offered annually to priority groups, but many people have not been vaccinated in over a year. We aimed to assess the association between time since booster vaccination and characteristics of breakthrough infection. We also assessed whether incident COVID-19 continued to associate with asthma exacerbations in boosted individuals, and whether risk of COVID-19-associated exacerbation was affected by time since vaccination.MethodsCOVIDENCE UK is a prospective, longitudinal, population-based study of COVID-19. We included adult participants who had received ≥1 booster vaccination. Time since vaccination was binarised at 6 months or 12 months according to vaccine eligibility subgroup. We used logistic, Cox, and linear regression to obtain adjusted estimates for the association between time since vaccination and breakthrough infection severity, symptom duration, and acute changes to health-related quality of life (measured by the EQ-5D-3L Index). We then assessed the association of incident COVID-19 with asthma exacerbations using multilevel mixed models, by time since vaccination.Results7391 boosted participants reported a breakthrough infection. Across all eligibility subgroups, greater time since vaccination associated with increased odds of infection requiring bedrest (vsmilder symptoms), with the highest odds for adults aged 65–75 years (1.83 [95% CI 1.51–2.23] when vaccinated >6 monthsvs≤6 months prior). However, we observed little evidence of association between time since vaccination and symptom duration. Vaccination >12 months prior (vs≤12 months) was associated with a small decrease in EQ-5D-3L Index among participants younger than 65 years (-0.03 points [-0.04 to -0.01]). Among 2100 participants with asthma, incident COVID-19 associated with increased risk of asthma exacerbation, both ≤12 months after vaccination (OR 5.31 [4.36–6.48]) and later (6.06 [3.23–11.38]), with a greater difference in point estimates when specifically considering severe asthma exacerbations (6.82 [4.88–9.54] for ≤12 monthsvs10.06 [3.90–25.92] for >12 months).ConclusionLonger time since booster vaccination consistently associates with more severe breakthrough infections, and may potentially increase risk of severe asthma exacerbations. These findings highlight the importance of ensuring those currently eligible receive their booster vaccinations, and the need for research on further vaccinations in people with asthma no longer eligible for boosters.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study

Vivaldi,

Talaei,

Pfeffer

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Tuberculosis and osteoporotic fracture risk: development of individualized fracture risk estimation prediction model using a nationwide cohort study

Choi,

Shin,

Jung

et al. 2024

Front. Public Health

Self Cite

View full text Add to dashboard Cite

PurposeTuberculosis (TB) is linked to sustained inflammation even after treatment, and fracture risk is higher in TB survivors than in the general population. However, no individualized fracture risk prediction model exists for TB survivors. We aimed to estimate fracture risk, identify fracture-related factors, and develop an individualized risk prediction model for TB survivors.MethodsTB survivors (n = 44,453) between 2010 and 2017 and 1:1 age- and sex-matched controls were enrolled. One year after TB diagnosis, the participants were followed-up until the date of fracture, death, or end of the study period (December 2018). Cox proportional hazard regression analyses were performed to compare the fracture risk between TB survivors and controls and to identify fracture-related factors among TB survivors.ResultsDuring median 3.4 (interquartile range, 1.6–5.3) follow-up years, the incident fracture rate was significantly higher in TB survivors than in the matched controls (19.3 vs. 14.6 per 1,000 person-years, p < 0.001). Even after adjusting for potential confounders, TB survivors had a higher risk for all fractures (adjusted hazard ratio 1.27 [95% confidence interval 1.20–1.34]), including hip (1.65 [1.39–1.96]) and vertebral (1.35 [1.25–1.46]) fractures, than matched controls. Fracture-related factors included pulmonary TB, female sex, older age, heavy alcohol consumption, reduced exercise, and a higher Charlson Comorbidity Index (p < 0.05). The individualized fracture risk model showed good discrimination (concordance statistic = 0.678).ConclusionTB survivors have a higher fracture risk than matched controls. An individualized prediction model may help prevent fractures in TB survivors, especially in high-risk groups.

show abstract

Long-Term Impacts of COVID-19 on Severe Exacerbation and Mortality in Adult Asthma: A Nationwide Population-Based Cohort Study

Cited by 2 publications

References 42 publications

COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study

COVID-19 severity and risk of SARS-CoV-2-associated asthma exacerbation by time since booster vaccination: a longitudinal analysis of data from the COVIDENCE UK study

Tuberculosis and osteoporotic fracture risk: development of individualized fracture risk estimation prediction model using a nationwide cohort study

Contact Info

Product

Resources

About